Table 3.
In vitro models utilizing CLL-cell stimulation with recombinant factors.
| Recombinant Factor (Concentration) | Duration in Days | Purification | CLL Viability | CLL Proliferation | Ref. |
|---|---|---|---|---|---|
| trimeric anti-CD40L moAb, IL4 (20 ng/mL) | 4 | PBMCs | - | [3H]TdR uptake (56% of cells with a high rate of DNA synthesis) |
[50] |
| trimeric anti-CD40L moAb (0.5 μg/mL) | 3 | PBMCs | 55% (22% *) | cell cycle (5.3% of proliferating cells); 31% samples non-responding |
[52] |
| IL4 (2 ng/mL), CD40L plus enhancer (100 ng/mL) | 7 | CLL | ~80% (40–80% *) | - | [12] |
| CD40L or anti-CD40 moAb, IL4 (10 ng/mL), IL21 (20 ng/mL) | 1.6 | PBMCs | - | [3H]TdR uptake; BrdU cell cycle, 25% cells in S+G2/M phase (0.7–7.8% *) |
[11] |
| CpG (5 μg/mL), IL21 (50 ng/mL) | 2.3 | CLL | no difference from control | [3H]TdR uptake, significantly increased proliferation with addition of IL21 | [83] |
| histidine-tagged CD40L (50 ng/mL), anti-polyhistidin mAb (5 μg/mL), CpG (10 μg/mL), IL2 (50 ng/mL), IL10 (50 ng/mL), IL15 (10 ng/mL), and IL6 (50 ng/mL), in specific time-dependent sequence |
7 | CLL | differentiation into antibody-producing cells | [84] | |
| IL15 (15 ng/mL), CpG (1.5 μg/mL) | 6 | CLL | 60–80% | CSFE (~70% divided cells) | [64] |
| IL15 (15 ng/mL), CpG (1.5 μg/mL) | 5 | PBMCs | <5% difference from control | CSFE (significantly increased cell division) | [78] |
| anti-IgM (10 µg/mL), trimeric CD40L (100 ng/mL), IL4 (10 ng/mL), and IL21 (25 ng/mL) | 6 | CLL | - | CSFE (41% of CLL samples proliferating) | [44] |
* In the brackets are results from control CLL samples cultured in standard conditions.